Salim Syed
Stock Analyst at Mizuho
(2.06)
# 2,853
Out of 4,732 analysts
76
Total ratings
36.07%
Success rate
-3.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $10.99 | +100.18% | 5 | Nov 21, 2024 | |
| NKTX Nkarta | Maintains: Outperform | $20 → $16 | $2.47 | +547.77% | 7 | Nov 21, 2024 | |
| GILD Gilead Sciences | Maintains: Outperform | $90 → $100 | $91.84 | +8.89% | 6 | Nov 21, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $99 → $103 | $45.74 | +125.19% | 6 | Nov 21, 2024 | |
| BIIB Biogen | Maintains: Outperform | $251 → $207 | $140.55 | +47.28% | 15 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $85.30 | +91.09% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $6.57 | +173.97% | 4 | Aug 16, 2024 | |
| AMGN Amgen | Maintains: Neutral | $223 → $235 | $272.11 | -13.64% | 7 | May 9, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $21.47 | +58.36% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $40.53 | +144.26% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $33.79 | +56.85% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $1.73 | +246.82% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.39 | +1,410.79% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $14.49 | +148.45% | 1 | Nov 16, 2022 |
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $10.99
Upside: +100.18%
Nkarta
Nov 21, 2024
Maintains: Outperform
Price Target: $20 → $16
Current: $2.47
Upside: +547.77%
Gilead Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $90 → $100
Current: $91.84
Upside: +8.89%
Cytokinetics
Nov 21, 2024
Maintains: Outperform
Price Target: $99 → $103
Current: $45.74
Upside: +125.19%
Biogen
Nov 21, 2024
Maintains: Outperform
Price Target: $251 → $207
Current: $140.55
Upside: +47.28%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $85.30
Upside: +91.09%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $6.57
Upside: +173.97%
Amgen
May 9, 2024
Maintains: Neutral
Price Target: $223 → $235
Current: $272.11
Upside: -13.64%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $21.47
Upside: +58.36%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $40.53
Upside: +144.26%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $33.79
Upside: +56.85%
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $1.73
Upside: +246.82%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.39
Upside: +1,410.79%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $14.49
Upside: +148.45%